
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Actinogen Medical Limited is a biotechnology business based in Australia. Actinogen Medical shares (ACW) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Actinogen Medical has a trailing 12-month revenue of around $3.5 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, Actinogen Medical's share price has had significant negative movement.
Its last market close was $0.022, which is 26.67% down on its pre-crash value of $0.03 and 46.67% up on the lowest point reached during the March crash when the shares fell as low as $0.015.
If you had bought $1,000 worth of Actinogen Medical shares at the start of February 2020, those shares would have been worth $457.14 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $628.57.
52-week range | $0.015 - $0.0565 |
---|---|
50-day moving average | $0.0272 |
200-day moving average | $0.0237 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.009 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.022 on 2020-10-22
1 week (2021-01-07) | 4.76% |
---|---|
1 month (2020-12-17) | 10.00% |
3 months (2020-10-16) | -12.00% |
6 months (2020-07-17) | -4.35% |
1 year (2020-01-17) | -35.29% |
---|---|
2 years (2019-01-17) | -61.40% |
3 years (2018-01-17) | -48.84% |
5 years (2016-01-15) | -60.00% |
Revenue TTM | $3.5 million |
---|---|
Gross profit TTM | $3.5 million |
Return on assets TTM | -23.95% |
Return on equity TTM | -40.15% |
Profit margin | -151.59% |
Book value | 0.01 |
Market capitalisation | $26.2 million |
TTM: trailing 12 months
We're not expecting Actinogen Medical to pay a dividend over the next 12 months.
Actinogen Medical's shares were split on a 1:2 basis on 3 December 2013. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Actinogen Medical shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Actinogen Medical shares which in turn could have impacted Actinogen Medical's share price.
Over the last 12 months, Actinogen Medical's shares have ranged in value from as little as $0.015 up to $0.0565. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Actinogen Medical's is 2.4723. This would suggest that Actinogen Medical's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.